Platelets are chief effector cells in hemostasis. In addition, they are multifaceted inflammatory cells with functions that span the continuum from innate immune responses to adaptive immunity. Activated platelets have key thromboinflammatory activities in a variety of vascular disorders and vasculopathies. Recently identified inflammatory and immune activities provide insights into the biology of these versatile blood cells that are directly relevant to human vascular diseases. (Circ Res. 2013;112:1506-1519.) The online-only Data Supplement is available with this article at http://circres.ahajournals.org/lookup/suppl/
P latelets are highly specialized for hemostasis and are first responders in vascular injury and endothelial disruption. This is traditionally the most well-known function of platelets, and platelet-dependent hemostasis is intensely studied. 2 Nevertheless, platelets are also inflammatory effector cells and have activities across the spectrum from acute inflammation to adaptive immunity. [3] [4] [5] [6] There is evidence that the inflammatory specializations of platelets, like their specializations for hemostasis, are evolutionarily driven adaptations that facilitate host defense, tissue repair, and protection against pathogens. 5, 6 Furthermore, platelets provide key central links between the inflammatory and hemostatic limbs of the host defense system, contributing to integration of vascular and wound repair and maintenance of tissue integrity. 5, 7, 8 The inflammatory activities of platelets also contribute to many organ-localized and systemic diseases with inflammatory components, however, on the basis of existing evidence and reasonable inference in conditions in which observations are incomplete. 6 It is intriguing that the ancient author Celsus, writing in Rome in the 1st century AD, described an apparent link between blood clots and pathological inflammation (see introductory quote), 1 although platelets had not yet been discovered in his time, 9 and delineation of their activities in vascular diseases and inflammatory syndromes is much more recent.
Human platelets respond with multiple innate immune effector activities when signaled by endogenous agonists generated or released in hemostasis and inflammation, by microbial toxins, or by many microbial pathogens. Key innate immune activities of platelets include release of chemokines, cytokines, and other mediators and interactions with endothelial cells, monocytes, and neutrophils, which are also critical responders in innate immunity and acute inflammation ( Figure 1 ; Online Table I ). [3] [4] [5] [6] [10] [11] [12] In addition, however, activated human platelets operate across the immune continuum and have a substantial armamentarium of adaptive immune activities. [3] [4] [5] [6] These include synthesis and release of pleiotropic immune mediators, including interleukin (IL)-1β, CD40 ligand (CD40L), and/or regulated upon activation, normal T cell expressed presumed secreted (RANTES), and interaction with lymphocyte subclasses and dendritic cells. 5, 6 Newly recognized inflammatory activities of platelets, including toll-like receptor (TLR)-mediated responses and the ability to trigger neutrophil extracellular trap (NET) formation ( Figure 2 ), continue to emerge. Here, we emphasize some of the recently discovered and rapidly evolving aspects of the biology of platelets in the immune continuum and the spectrum of inflammation and provide an overview of inflammatory activities of platelets in vascular diseases and vasculopathies. Because of space limitations, we telegraphically profile many topics that have been previously reviewed in comprehensive fashion. We also include additional online-only Supplementary Data to expand some of these issues.
Inflammatory Repertoire of Platelets Thrombosis and Inflammation: Linked Outcomes of Platelet Activation
Many functions of activated platelets that are induced by classic hemostatic agonists, such as thrombin and ADP, and that, for many years, were thought to exclusively mediate hemostasis and thrombosis are now known to also contribute to inflammatory and immune responses ( Figure 1 ; Online Table  I) . 5, 13 Traditional prothrombotic activities that are also proinflammatory include adhesion and aggregation, 14 display of surface molecules that favor generation of thrombin, 15 binding of fibrinogen, 16, 17 and interaction with the fibrin mesh of clots (Campbell R, PhD, Vieira-de-Abreu A, PhD, Weyrich A, PhD, manuscript in preparation, 2013). 17 Thrombin and fibrinogen are key proinflammatory factors in addition to being essential components of the coagulation cascade. 18, 19 Activated platelets can also synthesize tissue factor 5 that has complex roles in inflammation in addition to its critical procoagulant activities. 20 Platelets likely evolved from multifunctional defensive cells with the capacity to immobilize and kill pathogens, seal wounds, and repair tissues. [3] [4] [5] 21 Modern procoagulant and proinflammatory specializations of platelets and the ability to link inflammation and hemostasis and sense pathogens 5, 21, 22 thus may have ancient origins in host defense. Nevertheless, thromboinflammatory activities of platelets contribute to a large number of vascular diseases.
Platelet Receptors, Activation Pathways, and Integrins
Platelets have a diverse array of surface receptors that are linked to intracellular signaling cascades and that trigger cellular activation and key functional responses. 23, 24 Many induce and regulate hemostatic functions of activated platelets [23] [24] [25] [26] [27] and are targets for antiplatelet therapies in thrombotic diseases. 26, 28, 29 Many also link activation of platelets to proinflammatory responses, 5, 6 in addition to triggering prothrombotic signaling cascades. [23] [24] [25] [26] [27] [28] [29] G protein-coupled receptors and their intracellular pathways 24, 26 are chief examples (Online Table I ), but a variety of receptor-mediated pathways of platelets induce both inflammation and thrombosis. 5, 23 Inside-out signaling, also termed activation, of integrin α IIb β 3 , a central downstream effector response that is essential for normal hemostasis, 16 mediates pathological thrombosis 25, 28, 29 and can amplify inflammation. 5, 6 Activation of integrin α IIb β 3 is induced by a signaling cascade terminating in RAP1, Kindlin 3, and Talin. 24, 26, 30, 31 Several other integrins also mediate adhesive activities of activated platelets 17, 23, 27 and may participate in inflammatory interactions. 5, 31 Integrin signaling is bidirectional, and components of the inside-out cascade that mediate activation of integrin α IIb β 3 , 16, 30, 32 including Kindlin 3 33 and RAP1, 34 participate in outside-in signaling. Outside-in signaling of α IIb β 3 triggers or amplifies functional responses of platelets that have both hemostatic 16, 24, 32 and inflammatory 5, 6 consequences.
Platelet Immunoreceptors and TLRs
Some platelet surface receptors have been termed immunoreceptors because of their ligand recognition specificities and features of their molecular structures. 35 Platelet Fc receptors (FcγRIIA, FcεRI, and FcαRI), glycoprotein VI (GPVI), and C-type lectin-like receptor 2 are among these. 5, 6, 23, 35 Platelet Fc receptors bind immunoglobulins and immune complexes, providing direct mechanisms for immune recognition and signaling. 23, 35, 36 GPVI, which is uniquely expressed by platelets, is a major receptor for collagen with signaling activities in hemostasis and inflammation (Online Table I ). 6, 37 C-type lectin-like receptor 2, like GPVI, has emerging activities in platelet-dependent hemostasis, vascular integrity, and inflammation, including regulation of lymphangiogenesis in mouse models. 6, 37 Human platelets and platelets and thrombocytes from other mammals and vertebrates express TLRs. [4] [5] [6] 23, 38, 39 Intracellular and cell surface TLRs detect microbes and microbial products and transmit signals to inflammatory and immune transduction pathways. TLRs also recognize endogenous host-derived danger-associated molecular patterns, in addition to microbial pathogen-associated molecular pattern motifs. [40] [41] [42] The presence of TLRs on platelets is persuasive evidence that they evolved as immune effector cells and provides a molecular basis for their activities as pathogen sensors. 4, 5, 21, 38, 39 Together with other classes of receptors with immune signaling activities, 5, 23, 35 platelet TLRs provide a molecular basis for intravascular immune surveillance 43 and for pathological inflammatory and immune activities. [4] [5] [6] 44 As with prothrombotic receptors, [24] [25] [26] platelet TLRs may be engaged in parallel or in sequence with other receptors and may act cooperatively. 5, 6, 36 Megakaryocytic cell lines and megakaryocytes also express TLRs, 38 indicating that the TLR signaling may regulate thrombopoiesis and other megakaryocyte functions in the marrow 4 and lungs. 8 Human and mouse platelets express multiple TLRs at the mRNA and protein levels. [4] [5] [6] 38, 39 TLR4 is the most extensively studied. 6, 21, 23 Early reports indicated that platelets from several species bind or respond to lipopolysaccharide (LPS), suggesting the presence of one or more receptors. 6 In vitro experiments with isolated human platelets indicated that LPS amplifies responses triggered via Fc receptors 36 and that the endotoxic backbone of LPS, lipid A, can directly induce aggregation and serotonin secretion. 45 After molecular characterization of TLR4, the major immune receptor for LPS, 42, 46 its expression was reported on human and murine platelets, [47] [48] [49] [50] although it was not detected in 1 previous study. 51 In vitro experiments also demonstrated binding of LPS to platelet TLR4. 50, 52, 53 Binding of LPS to platelets may increase their consumption and phagocytosis in hemolytic uremic syndrome and autoimmune thrombocytopenic purpura. 52, 54 Variable changes in surface expression of TLR4 on freshly isolated platelets in response to thrombin have been reported. 39, 50, 52 One study indicated that binding of LPS to freshly isolated washed human platelets increases with thrombin stimulation and that TLR4 and P-selectin on the surfaces of activated human platelets cooperatively bind LPS. 52 Surface display of TLR4 on human platelets in stored concentrates was reported to decrease after activation. 48 A previous report found no evidence for direct activation of human platelets by TLR4 or for modulation of G-protein-coupled receptor-triggered platelet activation responses by LPS and concluded that TLRs may be vestigial molecular remnants bequeathed to platelets by megakaryocytes. 49 Subsequent studies of platelet responses to LPS in vitro describe contradictory results that are both perplexing and intriguing (Online Table II ). In some experiments, LPS did not induce typical activation responses of human or murine platelets, including shape change, aggregation, or surface translocation of P-selectin and did not enhance activation triggered by classic agonists, 47, 53, 55, 56 similar to results in the previous survey. 49 In others, however, LPS potentiated activation responses triggered by subthreshold concentrations of thrombin or collagen and directly induced actin cytoskeleton rearrangement, aggregation, binding of PAC-1 antibody (which recognizes activated integrin α IIb β 3 ), fibrinogen binding, degranulation of α and dense granule markers, display of CD40 ligand (CD40L), adhesion of platelets to cultured endothelial monolayers, platelet-neutrophil interaction and NET formation, and splicing of pre-mRNAs coding for IL-1β and tissue factor and synthesis of these protein products (most of these functional activities are discussed in this review). 48, 52, 53, [56] [57] [58] [59] There is no clear explanation for these discrepancies, but some of the factors may include variable potencies and structural features of LPS types from different bacterial sources, 45, 52, 58 delayed and more protracted responses of platelets to TLR4 engagement compared with activation via classic prothrombotic receptors (Online Table I ), 57 use of isolated washed platelets vs plateletrich plasma or platelets supplemented with plasma, serum, or recombinant or purified CD14 and LPS binding protein in key experiments. 52,57-59 CD14 and LPS binding protein are blood proteins that facilitate recognition of LPS by TLR4 42, 46 and are likely critical in the efficiency of binding of LPS to platelet TLR4 as with other cells that express this TLR family member. As examples, platelets in plasma, but not washed platelets, adhered to LPS-treated cultured endothelium; 52 the concentration of LPS required to potentiate collagen-induced platelet aggregation was 5-to 10-fold lower in platelet-rich plasma than in washed platelets; 58 and rCD14 and LPS binding protein facilitated pre-mRNA splicing by LPS-treated platelets. 57, 59 The signaling pathways that mediate responses of platelets to LPS have not been comprehensively defined, although key components that are required for TLR4 signaling in other cells are present. In addition to TLR4, myeloid differentiation factor 2, a lipoprotein binding protein family member that associates with TLR4 near its extracellular N-terminal domain, 23 is expressed on human platelets. 58, 60 CD14 also has been detected on the plasma membranes of resting human platelets in some, but not all, studies and may be primarily soluble CD14 derived from plasma. 52, 58, 59 Isolated human platelets or platelets in platelet-rich plasma did not bind anti-CD14 antibody in the resting state or when stimulated with thrombin, but binding of the antibody to platelets in plateletrich plasma increased in response to pretreatment with LPS. 52 At the intracellular face, myeloid differentiation marker 88 (MyD88), which is essential for downstream signaling by most TLRs, 42 is present in human platelets, 58, 60 and small molecule inhibitors of MyD88 interrupt LPS signaling. 59 Further, MyD88, in addition to TLR4, is required for LPS signaling of platelets based on studies of mice with mutations in TLR4 that make them hyporesponsive or unresponsive to LPS, TLR4 −/− mice, or MyD88 −/− mice. 47, 50, 52, 58, 59 None of these experiments examined platelet-specific genetic modifications of TLR4 or MyD88. Distal components of the canonical MyD88 pathway, 42 including TIR domain-containing adaptor protein, IL-IR-associated kinase 1, IL-IR-associated kinase 4, and TNFR-associated factor 6 are also present in human platelets based on experimental inhibition of their activities and other approaches. 22, 59, 60 Downstream from the MyD88 cascade there is evidence for rapid phosphorylation of Jun N-terminal kinase and AKT (within minutes) that is associated with more delayed functional responses. 59 A TLR4/MyD88-dependent activating pathway involving cyclic GMP, protein kinase G, and nitric oxide synthase also has been described, and it was suggested that this mechanism can inhibit or activate platelets depending on the concentrations of LPS. 58 This might explain inhibition of platelet activities by LPS in some earlier reports. 61, 62 Taken together, the studies reported to date suggest that there are gaps in our understanding of signaling cascades triggered by platelet TLR4, and that novel pathways may be involved. It is unknown whether recently identified platelet signaling cascades, such as those involving mammalian target of rapamcyin, 63-65 ADP-ribosylation factor 6 (Arf6-GTP), [66] [67] [68] or others, 24 mediate LPS-triggered responses.
In vivo experiments also indicate that LPS activates platelets, although complex signaling interactions involving parallel activation of myeloid leukocytes and endothelial cells occur as well. Challenge of mice or rabbits with LPS causes thrombocytopenia and time-dependent accumulation of platelets in the lungs and liver with the magnitude influenced by the microbial origin of the LPS. 47, 50, 53, [69] [70] [71] [72] [73] Platelet accumulation in microvessels of mice injected with LPS has been demonstrated using spinning-disc confocal microscopy and transgenic mice expressing endogenously labeled integrin subunit α IIb or in vivo labeling of platelets with anti-α 2 integrin subunit (CD49) antibody. 73 In other models, LPS induced accumulation of platelets in mesenteric vessels of rats 74 and cremasteric veins of mice, 55, 73 and promoted platelet-dependent thrombus formation in ferric chloride-injured carotid arteries of mice. 58 These responses were abrogated in mice with disabling mutations of TLR4 or in animals genetically deficient in TLR4 or MyD88. 47, 50, 55, 58 Maximal tumor necrosis factor-α generation is dependent on platelet TLR4 in mice challenged with LPS. 50 Thrombocytopenia induced by LPS in mice may involve effects on megakaryocytes in addition to circulating platelets. 75 Administration of LPS to human subjects under controlled conditions causes thrombocytopenia, alterations in CD40L on platelets, and formation of platelet-monocyte aggregates, [76] [77] [78] consistent with some of the studies with surrogate models and establishing translational relevance for them.
TLR2 on platelets has not been examined as extensively as TLR4, but it is clearly an important inflammatory receptor. TLR2, which heterodimerizes with TLR1 and TLR6, may be the most promiscuous of TLRs in terms of ligand recognition and binds lipopeptides, lipoproteins, peptidoglycans, and lipoteichoic acids from Gram-positive bacteria, some LPS species, and some fungal and mycobacterial products. 38, 58 Human and mouse platelets express TLR2, and human platelets express TLR1 and TLR6. [48] [49] [50] Surface display of TLR2 may increase with cellular activation. 39 Most, but not all, 49 reports indicate that treatment of human platelets with ligands for TLR2 triggers thromboinflammatory activities. These responses seem to be differentially regulated by intracellular pathways distinct from those activated by classic prothrombotic receptors (Online Table I ) and include inside-out signaling of integrin α IIb β 3 , aggregation, adhesion to collagen, P-selectin translocation, generation of reactive oxygen intermediates, and splicing of IL-1β pre-mRNA. 57, [79] [80] [81] In addition, the synthetic TLR2/TLR1 agonist PAM 3 CSK4 induces formation of plateletneutrophil aggregates in whole human blood. 80 PAM 3 CYSK4 and a bacterium that is recognized by TLR2 triggered platelet activation in wild-type mice that was reduced in TLR2 −/− animals. 80 Engagement of TLR2 on murine megakaryocytes and a megakaryocyte cell line altered mechanisms that regulate megakaryocyte maturation; in addition, treatment of mice with Pam 3 CSK4 increased megakaryocyte maturation and platelet numbers in wild-type animals but not those deficient in TLR2, indicating the TLR2 on megakaryocytes may regulate megakaryopoiesis and thrombopoiesis in inflammation. 38, 82 TLR9 is the most intriguing member of the platelet TLR repertoire. TLR9 is basally expressed on the plasma membranes and in the cytoplasm of resting human platelets, and its surface display is increased when platelets are activated by thrombin. 5, 48, 50, 83 In other cell types, TLR9 is exclusively intracellular and is restricted to endosomal domains. 40, 42 Recent studies of mouse and human platelets and megakaryocytes demonstrate that TLR9 is distributed to a newly identified compartment, termed the T granule, during proplatelet production and that type IV collagen increases TLR9 surface expression. Certain oligodeoxynucleotides, which are known synthetic ligands for TLR9, induce P-selectin translocation and also increase TLR9 surface display. 83 TLR9 recognizes unmethylated CpG islands in viral and bacterial DNA, 5,83 suggesting a previously unrecognized pathogen-sensing system in platelets. In addition, platelet TLR9 was recently reported to bind a carboxyalkylpyrrole protein adduct that may act as a danger-associated molecular pattern under conditions of oxidant stress, and to transmit signals triggering aggregation and degranulation via the MyD88 pathway. 84
Noncanonical Activities of Immune Transcriptional Regulators
In nucleated cells, signaling via the TLR/MyD88 pathway is a major mechanism of expression of cytokines and chemokines. Synthesis of many of these proteins is controlled by the nuclear factor κB (NF-κB) transcriptional regulatory system. 41, 42 Platelets are anucleate cells, however, and there is no evidence for transcriptional activity aside from mitochondrial transcription. Nevertheless, several NF-κB proteins are expressed by human platelets, 60, [85] [86] [87] [88] [89] and one, B cell lymphoma 3 (BcL-3), is induced in human and mouse platelets as a result of signal-dependent translation of constitutive BcL-3 transcripts (Online Table III ). 63, 64, 85 Interestingly, levels of transcripts for some NF-κB pathway members and TLR2 are altered in platelets from subjects with cardiovascular risk factors and obesity. 90 Together, these observations suggest that NF-κB family members have physiological activities in anucleate platelets independent of their traditional roles in transcription, 85, 86 although transcriptional regulation clearly occurs in megakaryocytes. 38, 88 Consistent with this prediction, Bcl-3 was found to be an intracellular regulator of clot retraction by human and mouse platelets. 63 More recently, a complex of NF-κB, inhibitor of κB (IκB), and protein kinase A was reported to exert negative feedback activities that modulate cytoskeletal reorganization and aggregation in platelets stimulated by thrombin or collagen. [87] [88] [89] It is not yet known whether pathways regulating, or regulated by, NF-κB are altered by upstream signaling from TLR2, TLR4, or TLR9 and MyD88 in platelets. Additional nuclear factors with noncanonical activities are also expressed by these cells. 89 
Degranulation, Secretion, and Translocation: Inflammatory Signaling and Effector Mechanisms of Activated Platelets
Activated platelets have diverse mechanisms for inflammatory signaling and transcellular transfer of biologically active factors and molecular information. 3, 5, 6 This is, in part, engendered by diverse mechanisms for release of signaling factors or their display on the platelet surface (Online Table III ).
Rapid degranulation and secretion of preformed soluble factors are a classic activation responses of platelets. 4, 5, 44, 91 More than 300 proteins may be released, depending on the agonist. The α granules and dense granules are the most rigorously characterized intracellular storage organelles of platelets. 91 Distinct subpopulations of α granules have been reported in murine platelets, 4,92 but differential release of α-granule cargo predominantly may be a kinetic variable when human platelets are stimulated. 93 Factors released from α granules and dense granules contribute to hemostasis, thrombosis, angiogenesis, endothelial barrier modulation, and inflammatory signaling (Online Table III ). [3] [4] [5] [6] 8, 44, 91 Examples of recently reported activities of secreted platelet factors include increased vascular permeability in experimental arthritis mediated by serotonin, 94 modification of inflammation-associated hemorrhage by triggering receptor expressed on myeloid cells-like transcript 1, 95 and modulation of angiogenesis. 96 Some factors that are degranulated by activated platelets are not immediately released into solution but are retained on the plasma membrane after surface translocation. P-selectin, which mediates platelet-leukocyte interactions and intercellular signaling, is a key example (Online Table III ). 5, 44 Studies in mice and humans indicate that fibrinogen, another α-granule constituent, contributes to maintenance of intracellular and cell surface of P-selectin. 97, 98 Additional constitutive or newly synthesized factors can also mediate spatially regulated juxtacrine intercellular signaling at the platelet surface. Platelet-activating factor (PAF)-a phospholipid-signaling molecule-CD40L, and IL-1β are examples. 5, 6 New platelet mediators, compartments, and intercellular signaling mechanisms continue to be identified. Human βdefensin-1, an antimicrobial peptide not previously known to be present in platelets, is released in response to staphylococcal α-toxin, induces formation of NETs (Figure 2) , and kills Staphylococcus aureus in vitro. 99 In resting human platelets, human β-defensin-1 is found in an intracellular compartment distinct from classic granules. 99 As noted previously, TLR9 is also localized in a unique intracellular compartment. 83
Synthetic Pathways, the Platelet Transcriptome, and Signal-Dependent Alterations in the Platelet Proteome
The platelet is a synthetic cell when it is activated. Traditional synthetic pathways include those that regulate production of thromboxane A 2 , 13 PAF, [100] [101] [102] and reactive oxygen species. 13, 80, 103 Most investigators discarded the possibility that platelets synthesize new proteins because they are anucleate 104 -although platelets were known to have mRNAs in their intracellular arsenal. 64, 105 More recently, we and others found that many of these mRNA transcripts can be translated in a signal-dependent fashion by activated platelets, and that this alters the platelet proteome in functionally significant ways. 63, 64, 85, 106 This led to the unexpected discovery that platelets also have pre-mRNAs and a spliceosome-dependent mechanism for their processing to mature transcripts and subsequent translation (Online Table IV ). [107] [108] [109] The platelet transcriptome is now being comprehensively examined in the basal state and in disease using new approaches, including genome-wide next-generation RNA sequencing. 110 Diversity in the constitutive platelet transcriptome continues to emerge, and it is now known that it includes mi-croRNAs in addition to processed mRNA and pre-mRNA transcripts. 108, 110, 111 There is evidence that megakaryocytes differentially sort transcripts to platelets during thrombopoiesis, and that this is a mechanism for regulating protein synthesis by the circulating cells. 112 In parallel, diversity in the posttranscriptional pathways for transcript processing and regulated translation has been identified in the platelet repertoire. 64, 113 There is evidence that these newly discovered mechanisms influence the platelet proteome and functions in thrombosis, inflammation, and immune responses. 5, 6, 64, 113 There is also evidence that the platelet transcriptome is altered in infection and disease 5,6,56,90,110 (Rondina et al, manuscript in preparation).
Protein products with functional relevance in inflammation and hemostasis are synthesized in a signal-dependent fashion by activated human platelets (Online Table III ). 56, 57, 59, 63, 64, 85, [106] [107] [108] [109] [112] [113] [114] [115] [116] Synthesis of IL-1β provides a physiologically relevant example of intricate posttranscriptional pathways that are involved. 5, 6, 64 Quiescent human platelets have the IL-1β pre-mRNA but little or no processed mature IL-1β transcript or IL-1β protein. 108 When they are activated by thrombin or other classic agonists in the presence of fibrinogen, they synthesize pro-IL-1β protein, some of which is processed to the mature IL-1β cytokine. 107, 108 Human platelets have key components of the inflammasome, 6 which mediates conversion of pro-IL-1β to mature IL-1β. 117 Dissection of the molecular steps upstream from IL-1β protein synthesis and processing yielded a regulatory mechanism unexpected in mammalian biology. 118 Key studies demonstrated evidence that megakaryocytes deliver the IL-1β pre-mRNA and a functional spliceosome to platelets during proplatelet formation, and that spliceosome activity is triggered in a signal-dependent fashion in activated platelets. 108 The signal-dependent splicing pathway is controlled by Cdc-like kinase 1, a kinase not previously known to be present in platelets. 57, 59, 109 TLRs and immunoreceptors also activate this mechanism: LPS in the presence of CD14 and LPS binding protein, 57,59 engagement of TLR2, 57 and engagement of FcαRI 114 -an immunoreceptor for IgA on platelets-trigger splicing of IL-1β pre-mRNA and synthesis of IL-1β protein. IL-1β is a pleiotropic cytokine that has been called the gatekeeper of inflammation. 119 Thus, this regulated synthetic pathway provides platelets with a powerful mechanism to influence inflammatory and immune events. 5, 6, 107, 108 In vitro and in vivo studies indicate that activated human platelets signal endothelial cells, leukocytes, and vascular smooth muscle cells by releasing IL-1β in solution or its transport in microvesicles or by juxtacrine signaling. 6 Recent in vivo observations also indicate that release of IL-1β in platelet microvesicles is one mechanism by which platelets communicate with and activate extravascular cells. 120, 121 An important feature of signal-dependent translation of proteins by platelets is that it can continue for many hours after they are activated. 56, 85, [107] [108] [109] 112 In addition, some proteins can be basally synthesized continuously over many days by platelets stored ex vivo. 122 These and other aspects of regulated posttranscriptional protein expression are features of the new biology of platelets 64, 121 and also have clinical relevance to thromboinflammatory diseases 6 and transfusion medicine. 123 Prolonged synthesis of proteins by platelets also raises interesting questions about their contributions to the biochemical milieu of clots and thromboinflammatory lesions in vivo. Although the lifespan of platelets in the circulation and in vitro is known, 124 their longevity in thrombi and wounds has not been precisely determined, and they may persist and synthesize proteins and other factors for extended periods of time and in variable temporal patterns. In vitro studies indicate that thrombi may be reservoirs for IL-1β synthesized by platelets, 6,107 suggesting a mechanism for inflammatory properties of clots proposed by Celsus. 1
Platelet-Leukocyte Interactions
Activated platelets interact with circulating myeloid leukocytes and with lymphocytes of several classes. 5, 14 Binding of activated platelets to leukocytes enhances their adhesion to endothelium and transmigration under some experimental conditions and is an important mechanism that facilitates accumulation of neutrophils and monocytes in inflamed vessels and infected or injured tissues. 5, 6 As recent examples, platelets enhanced adhesion of CD14 high CD16 + monocytes to endothelial cells in vitro, 125 facilitated human and murine neutrophil transmigration across IL-1β-activated endothelial monolayers and in an inflamed cornea model, 126 and selectively enhanced monocyte recruitment to endothelium in mouse and human models of vascular inflammation. 127 Alternatively, platelets were recruited to sinusoidal microvessels in the livers of mice injected with LPS primarily by interacting with neutrophils that were already adherent to the endothelial surface. 73 Platelet depletion reduced monocyte emigration and parasite killing in a mouse model of Leishmania infection. 128 These observations illustrate diverse defensive and pathological consequences that may result from platelet-leukocyte interactions. 5, 6 In addition, platelet binding to exposed subendothelium is a mechanism to recruit myeloid leukocytes to injured vessels 6 and may be one that allows neutrophil accumulation at shear stresses that restrict or prevent their adhesion to endothelium under flow. 129 
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Activated platelets also bind to leukocytes in circulating blood, forming multicellular heterotypic aggregates. 5, 6, 44 In these interactions, binding of P-selectin on the plasma membrane of the activated platelet to P-selectin glycoprotein ligand 1 (PSGL-1) on the leukocyte is a dominant molecular event (Figure 3 ), although other adhesive mechanisms also have been described depending on the specific leukocyte subtype, species of origin, and experimental condition. 5, 6 Binding of P-selectin on activated platelets to PSGL-1 on leukocytes not only tethers the cells together but also delivers signals that induce integrin activation, trigger gene expression pathways, and induce other functional responses by the leukocytes. 5, 6, 44 Studies using whole human blood indicated that reciprocal platelet activation also occurs. 5, 6 Although such interactions of activated platelets with leukocytes have physiological inflammatory consequences, there is also evidence that they contribute to microvascular occlusion, thrombosis, and propagation of inflammatory damage in disease. 6, 44, 130, 131 Interactions of platelets with monocytes and neutrophils have been studied most. Platelet-monocyte aggregates are more stable than platelet-neutrophil complexes, in part, because of differential regulation of PSGL-1, 132, 133 and formation of platelet-monocyte aggregates may be the most sensitive and durable index of in vivo platelet activation in experimental and clinical conditions. 134 Platelet-monocyte aggregates have been detected in the blood of humans with a variety of diseases (Online Table V ). 6 Early studies demonstrated that P-selectin mediates binding of activated platelets to monocytes. 135, 136 Both intercellular adhesion and signaling are consequences of this molecular interaction (Figure 3) . 5, 44 Signals delivered to the monocyte by ligated PSGL-1 can be amplified by, and integrated with, signaling by PAF, RANTES, or other factors from the activated platelet or autocrine signaling by the monocyte. [136] [137] [138] [139] [140] [141] New expression of key proinflammatory cytokines and metalloproteinases, synthesis of tissue factor, and expression of cyclooxygenase 2 with generation of cyclooxygenase 2-dependent eicosanoids occur in response to signaling of human monocytes by platelets ( Figure 3 ). 130, 137, [140] [141] [142] [143] [144] [145] [146] [147] Differential signaling and monocyte synthetic responses can be detected in model conditions mimicking ruptured atherosclerotic plaques. 138 Molecular interactions between activated platelets and monocytes provide specific targets for therapeutic interruption of thromboinflammatory activities in vascular diseases. 28, 29, 125, 138, 140, 145 As with monocytes, binding of activated platelets to neutrophils, eosinophils, and basophils via P-selectin/PSGL-1 induces signaling and intercellular adhesion. 5 Platelet-neutrophil aggregates have been detected in blood samples from patients with inflammatory syndromes, 6 although as noted they may be more transient than platelet-monocyte aggregates. PSGL-1 engagement on human neutrophils triggers kinase cascades and chemokine synthetic pathways, 5, 44, 148 and in murine models it induces activation of β 2 integrins on neutrophils. 44, 149, 150 Activation of leukocyte α M β 2 integrin in this fashion may stabilize aggregation of activated platelets and leukocytes by allowing α M β 2 to recognize GPIb on the platelet or fibrinogen bound to platelet integrin α IIb β 3.
44 Activation of platelets in whole blood induces platelet-leukocyte aggregate formation and binding of tissue factor, factor Xa, and fibrinogen to the surfaces of neutrophils and monocytes; aggregates thus may be vehicles for local and systemic delivery of coagulation factors. 151, 152 In vitro modeling indicates that human neutrophils enhance fibrin deposition under flow in a fashion that is partly platelet-dependent. 153 Observations in humans and mouse models indicate that platelet-neutrophil aggregates contribute to increased pulmonary vascular permeability and a chronic inflammatory state in sickle cell disease. 154 Platelet-leukocyte interactions of this nature contribute to pathological vascular Figure 3 . Human platelets adhere to monocytes via P-selectin engagement of P-selectin glycoprotein ligand 1 (PSGL-1) and deliver signals that induce expression of proinflammatory gene products. Reproduced with permission from Lindemann 185 with permission of the publisher. COX-2 indicates cyclooxygenase 2; IL, interleukin; MCP, monocyte chemotactic protein; MIP, macrophage inflammatory protein; MMP, matrix metalloproteinase; PCR, polymerase chain reaction; RNA seq, genome-wide next generation RNA sequencing; TNF, tumor necrosis factor; and UPAR, urokinase plasminogen activator receptor.
inflammation and thrombosis in a variety of experimental and clinical syndromes 6 (Figures 4-6 ; Online Table V) . 155 NETs are extracellular lattices of chromatin, histones, and granule enzymes extruded by neutrophils via a unique cell death pathway sometimes termed NETosis (Figure 2 ). 156, 157 NETs capture and kill a variety of microbes, but there is also evidence that they mediate infectious and sterile vascular injury in sepsis, immune vasculitis, transfusion-related acute lung injury, venous thrombosis, and other syndromes. 6, 10, 156, 157 LPS-stimulated human platelets trigger NET formation under flow conditions and platelets are required for in vivo formation of NETs in mice challenged with LPS. 53, 158 Platelets and leukocytes accumulate and NETs are formed in lung microvessels in a murine model of transfusion-related acute lung injury, and platelet depletion, aspirin treatment, or blockade of integrin α IIb β 3 decrease NET formation and lung damage (Online Table V ). 159, 160 The signals from activated platelets that induce NETosis are not completely defined. NET formation by human neutrophils is induced by human βdefensin-1 from platelets activated by staphylococcal α-toxin ( Figure 2 ), 99 but this may not occur in mice because of species differences in defensin expression. 161 Interactions of activated platelets with lymphocytes, dendritic cells, and macrophages are key events with the potential to influence adaptive immune responses and contribute to chronic inflammatory and immune syndromes. 3, 5 Adaptive immune facets of the platelet repertoire complement the innate immune armamentarium of these cells. This has been progressively appreciated in recent evolution of the field. [3] [4] [5] Discovery that platelets express and release CD40La pivotal immune signaling molecule that is critical in T-celldependent isotype switching and generation of antibody subclasses by B cells and for dendritic cell activation-has been central in recognition of platelets as adaptive immune effector cells. 3, 5, 13, 39, 162 Additional activities of platelets, such as synthesis of IL-1β, also have the potential to initiate, amplify, or modify adaptive immune pathways. 5
Interactions of Platelets and Endothelium
Endothelial cells have potent mechanisms for restricting platelet activation at the uninjured vascular luminal surface, including enzymatic generation of prostacyclin and nitric oxide and degradation of ADP and ATP. 13, 163 There is also evidence that platelets signal uninjured endothelium and are critical for maintenance of basal endothelial barrier function in pulmonary and systemic vessels. 6, 8 Basal endothelial barrier properties regulate transvascular flux of water and solutes, contributing to the prevention of edema, and also prevent red blood cells extravasation and bleeding. In several experimental models, thrombocytopenia leads to leakiness of vessels. 8 Increased endothelial permeability secondary to disrupted barrier properties is a cardinal feature of inflammation mediated by LPS, cytokines, and other factors. This often occurs in the absence of profound thrombocytopenia, but in some cases inflammation and thrombocytopenia negatively influence barrier function in concert. 6, 95, 164 In mice, dramatic reduction in platelet numbers (to <2%-3% of control) sufficient to prolong tail-clip bleeding times did not cause spontaneous bleeding; in contrast, spontaneous hemorrhage into inflamed tissues occurred when thrombocytopenic animals were subjected to the cutaneous arthus reaction, LPS-induced lung inflammation, or cerebral ischemia. 164 A relatively small increase in platelet numbers (≈10%) afforded protection against spontaneous bleeding, and this was independent of classic mechanisms of platelet-dependent hemostasis mediated by integrin α IIb β 3 , GPIb, GPVI, and von Willebrand factor. 164 This protective effect may result from local delivery of barrier stabilizing factors and inhibition of neutrophil-mediated endothelial injury by platelets. 8, 165 Changes in these components of the platelet repertoire in inflammatory syndromes have not been examined. 8 More recently, GPV1 and C-type lectin-like receptor 2 were reported to be required for prevention of inflammatory hemorrhage by murine platelets, 166 at variance with some of the previous observations. 164, 165 Paradoxically, platelets also contribute to disruption of endothelial barrier integrity in inflammation. Many of these observations come from models of acute lung injury and the acute respiratory distress syndrome (Online Table V ). 8, 167 In one study, formation of platelet-neutrophil aggregates and their interaction with endothelium mediated increased pulmonary vascular permeability and alveolar inflammation in murine models of acid aspiration and sepsis. 168 In other lung or systemic models, platelets or platelet lysates trigger inflammation and edema or are required for maximal vascular barrier disruption. 6, 8, 94, 159, 160, 169, 170 Serotonin delivered by platelets was recently reported to increase synovial vascular permeability in murine experimental arthritis. 94 Serotonin also had endothelial barrier destabilizing properties or, in contrast, promoted barrier stabilization in several earlier studies. 8 As outlined previously, activated platelets synthesize and release IL-1β, a potent mediator of endothelial barrier destabilization and increased endothelial permeability. 5, 6 Thus, platelets have multiple mechanisms by which they can influence endothelial barrier integrity in inflammatory diseases. 6, 8 Studies of cultured human endothelial cells, cell lines, and animal models indicate that activated platelets can signal endothelium, inducing the expression of adhesion molecules, chemokines, and other proinflammatory factors, and that platelets interact directly or indirectly with the endothelium and with the subendothelium of inflamed or injured vessels (Figures 4-6 ). Functional consequences, inflammatory responses, and molecular mechanisms involved in these interactions have been reviewed in detail. 6, 14, 131, 171 Relevant reports are also cited here (Online Table V) . 52, 53, 57, 58, [72] [73] [74] 107, [125] [126] [127] 129, 159, 160 A recent study indicates that platelets may deliver RNA to endothelium and leukocytes, 172 suggesting a potential mechanism for complex intercellular information transfer.
Platelet Microparticles: Intravascular and Extravascular Signaling
Microparticles shed by megakaryocytes and platelets are subcellular vehicles for delivery of biologically active factors to vessels and to extravascular cells in hemostasis, thrombosis, and inflammation. [3] [4] [5] 113, 173 A variety of examples illustrate the potential for platelet-derived microparticles to drive inflammatory and immune events. Platelet microparticles mediate intercellular arachidonic acid transfer to other platelets and to endothelial cell, potentially amplifying activation responses 174 and modifying endothelial-monocyte interactions. 175 Platelet microparticles can deliver IL-1β 59, 107 and RANTES 176 to endothelium and transport newly synthesized tissue factor. 109 CD40L carried by platelet microparticles is a mechanism for lymphoid germinal center formation and antigen-specific IgG production. 162, 177 Microparticles from activated platelets bearing IL-1β and IL-1α signal synoviocytes and induce chemokine synthesis in vitro, and seem to fuel synovial inflammation in vivo. 120, 121 A variety of other experimental observations and clinical correlates indicate that microparticles are key components of the platelet repertoire in thromboinflammatory signaling and intravascular and extravascular communication. 121, 173 
Platelets as Mediators of Inflammation in Vascular Diseases
There are many examples of inflammatory vasculopathies, which are syndromes that involve intravascular, intimal, or vessel wall inflammation. They range in frequency from extremely common to rare and arcane, in presentation from acute to chronic, and in topography from localized to systemic. Inflammatory vasculopathies are profiled in Online Table V. Sepsis is a common, lethal, and informative example of acute systemic vasculopathy. Intravascular fibrin deposition and thrombosis, disrupted endothelial barrier function, and intravascular inflammation are key pathogenetic events. 6, 155, 178, 179 Although pathogens, LPS, and other microbial toxins can directly induce the pathological features of septic vasculopathy, clinical observations and animal studies support the central concept that molecular and cellular responses of the host are key to the pathogenesis of sepsis. 6, 178 There is substantial evidence that platelets are pivotal cellular effectors ( Figure 6 ). [4] [5] [6] 10, 171, 180 Each of the activities in the repertoire of activated platelets outlined in this review (Figure 1 ) has been implicated in the vasculopathy of sepsis (Online Table V ). 6 Activated platelets and platelet-leukocyte aggregates are detected in clinical samples and in animal models (which, however, do not absolutely recapitulate clinical sepsis), 6, 178 and there is evidence that platelet sequestration and deposition of plateletfibrin thrombi in microvessels are central mechanisms. 6, 53, [69] [70] [71] [72] [73] Sequestration of activated platelets bound to fibrin and leukocytes likely contributes to thrombocytopenia in sepsis, which is common and multifactorial. TLR-dependent signaling of platelets by LPS and other bacterial factors provides one mechanism for platelet activation in sepsis (Online Table  II ). [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [69] [70] [71] [72] [73] [74] [75] [76] [77] [78] [79] [80] [81] Activation of platelets by host factors generated in sepsis, including thrombin and PAF 6 (Online Table I ), provides a second mechanism. Pathological platelet responses, including degranulation, secretion, and synthesis (Online Tables III  and IV) , may contribute to altered endothelial barrier function that is central to sepsis and to involvement of multiple organs, including the lungs, in septic syndromes. 6, 8, 95, 164, 167 Platelet synthetic responses (thromboxane A 2 PAF, and IL-1β) have the potential to drive pathological interactions with endothelium and leukocytes and microvascular thrombosis (Figure 4 ). 6 Platelet-neutrophil interactions and platelet-triggered NET formation (Figure 2 ) are mechanisms of endothelial barrier destabilization and injury based on animal models and in vitro experiments. 8, 10, 53, 58, 73, 80, 99, 168 Clinical samples and human cell experiments indicate that platelet-monocyte interactions occur in sepsis, 6 and animal models suggest that platelets regulate cytokine generation in this condition. 50 The platelet transcriptome is altered in sepsis 56 (Rondina et al, manuscript in preparation), potentially imparting pathologically relevant changes in the platelet proteome in addition to diagnostic signatures. Platelet-derived microparticles may amplify systemic inflammation and thrombosis in sepsis. 4 Experimental and clinical observations establish a rationale for assessment of antiplatelet therapies in human sepsis. 180 Nevertheless, studies of this nature will be challenging because sepsis is a group of syndromes with poorly characterized subsets, a feature that often confounds clinical trials.
A number of other acute and subacute infectious vasculopathies (Online Table V ) provide important but incomplete insights into inflammatory activities of platelets. Severe malaria involving the brain and lungs has features of acute vasculopathy similar to those of sepsis, including intravascular accumulation of platelets, leukocytes, and fibrin and endothelial barrier disruption. There is substantial evidence that platelets are key immune effectors in severe malarial vasculopathy (Online Table V ). 6, 181 Intravascular interactions of platelets and monocytes may be central in this syndrome ( Figure 5 ). 6 Dengue provides an example of an acute viral-induced vasculopathy in which platelets may be critical (Online Table V ). The roles of platelets in many syndromes of infection-induced vasculitis and thrombosis 182 have not been comprehensively examined, however.
Atherosclerosis, which is chronic and affects vessels in a segmental fashion, is at the other extreme of the spectrum of inflammatory and immune vasculopathies ( Figure 6 ). Inflammation of the vessel wall is central to atherogenesis. As in sepsis, most of the activities in the platelet inflammatory and immune repertoire (Figure 1 ) have been implicated in initiation and progression of atherosclerotic plaques and in thromboinflammatory consequences of plaque rupture, which frequently punctuates the natural history of atherosclerosis (Online Table V) . 13, 171, 183 Both innate and adaptive immune activities of platelets 3,5 may contribute to the evolution of atherosclerotic lesions, 183 although this is incompletely studied.
Evidence for contributions of activated platelets to initiation and progression of atherosclerotic lesions includes experimental and clinical observations that platelets commonly adhere to fatty streaks and established plaques, and that platelets are activated by biochemical mediators thought to be important in atherogenesis, including oxidized low-density lipoproteins and oxidatively modified lipids. 183 Discovery that TLRs are in the platelet repertoire and that endogenous molecules and danger-associated molecular patterns with potential importance in atherogenesis may activate platelets via TLRs 84 -as with other cells 41, 42 -extends the potential initiating mechanisms. In Apoe −/− mice, a commonly used model of atherosclerosis, platelets were found to adhere to the intimas of arteries before lesions were detectable, genetic deletion of the α IIb subunit of integrin α IIb β 3 reduced lesional development, and circulating activated platelets secreted proinflammatory chemokines and formed platelet-monocyte aggregates in a P-selectin-dependent fashion, with leukocyte deposition on endothelial surfaces. These and other observations in murine models support key contributions of platelets to initiation and evolution of atherosclerotic plaques. 131, 171, 183 Clinical studies, including immunohistochemical analysis of atherosclerotic vascular tissue and assay of plasma and urine samples for markers of platelet release, suggest persistent platelet activation in atherosclerosis and in conditions that increase risk or accelerate the syndrome and that this drives atherosclerotic vascular inflammation. 13, 183 In parallel, many clinical and experimental observations indicate that platelet activation, cell-cell interactions, and inflammatory signaling are central in acute coronary syndromes and other thromboinflammatory complications of plaque rupture, and in responses to vascular intervention, including angioplasty and stent placement (Online Table V) . 13, [25] [26] [27] [28] [29] 134, 152, 183 Thus, activated platelets may be ubiquitous effector cells in all phases of vascular inflammation in atherosclerosis. Acute ischemic stroke resulting from cerebral artery stenosis, thromboembolic vascular occlusion, and cerebral infarction is now recognized as a thromboinflammatory syndrome with platelets contributing to inflammation in addition to vascular occlusion, 184 as in acute coronary syndromes (Online Table V) .
Many features of the inflammatory and hemostatic repertoire of activated platelets (Figure 1 ; Online Table I ) seem to be common in inflammatory vasculopathies, yet the syndromes are unique (Figures 4-6 ; Online Table V) . This, in part, clearly reflects the activities of other key cells. [10] [11] [12] It likely also reflects unique patterns of platelet responses to agonists that trigger and drive vascular inflammation-bacteria, fungi, and their products together with host factors in sepsis, parasitized erythrocytes and plasmodial toxins in malaria, oxidatively modified lipids, metabolic danger-associated molecular patterns, and plaque components in atherosclerosis. It likely also reflects the fact that the platelet repertoire is not yet completely cataloged,
